Age appropriateness is a major concern of pulmonary delivery devices, in particular of dry powder inhalers (DPIs), since their performance strongly depends on the inspiratory flow manoeuvre of the patient. Previous research on the use of DPIs by children focused mostly on specific DPIs or single inspiratory parameters. In this study, we investigated the requirements for a paediatric DPI more broadly using an instrumented test inhaler. Our primary aim was to assess the impact of airflow resistance on children’s inspiratory flow profiles. Additionally, we investigated children’s preferences for airflow resistance and mouthpiece design and how these relate to what may be most suitable for them. We tested 98 children (aged 4.7–12.6 years), of whom 91 were able to perform one or more correct inhalations through the test inhaler. We recorded flow profiles at five airflow resistances ranging from 0.025 to 0.055 kPa0.5.min.L？1 and computed various inspiratory flow parameters from these recordings. A sinuscope was used to observe any obstructions in the oral cavity during inhalation. 256 flow profiles were included for analysis. We found that both airflow resistance and the children’s characteristics affect the inspiratory parameters. Our data suggest that a medium-high resistance is both suitable for and well appreciated by children aged 5–12 years. High incidences (up to 90%) of obstructions were found, which may restrict the use of DPIs by children. However, an oblong mouthpiece that was preferred the most appeared to positively affect the passageway through the oral cavity. To accommodate children from the age of 5 years onwards, a DPI should deliver a sufficiently high fine particle dose within an inhaled volume of 0.5 L and at a peak inspiratory flow rate of 25–40 L.min？1. We recommend taking these requirements into account for future paediatric inhaler development.
References
[1]
Frijlink H, De Boer AH (2004) Dry powder inhalers for pulmonary drug delivery. Exp Opin Drug Deliv 1: 67–86. doi: 10.1517/17425247.1.1.67
[2]
Vidgren M, K？rkk？inen A, Karjalainen P, Paronen P, Nuutinen J (1988) Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 42: 211–216. doi: 10.1016/0378-5173(88)90177-9
[3]
Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, et al. (2013) Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 107: 37–46. doi: 10.1016/j.rmed.2012.09.017
[4]
Brocklebank D, Ram F, Wright J, Barry P, Cates C, et al.. (2001) Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 5.
[5]
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, et al. (2008) Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 102: 593–604. doi: 10.1016/j.rmed.2007.11.003
[6]
Pedersen S, Dubus JC, Crompton GK (2010) The ADMIT series ？ Issues in inhalation therapy. 5) Inhaler selection in children with asthma. Prim Care Respir J 19: 209–216. doi: 10.4104/pcrj.2010.00043
[7]
Goren A, Noviski N, Avital A, Maayan C, Stahl E, et al. (1994) Assessment of the ability of young children to use a powder inhaler device (Turbuhaler). Pediatr Pulmonol 18: 77–80. doi: 10.1002/ppul.1950180204
[8]
Bisgaard H, Pedersen S, Nikander K (1994) Use of budesonide Turbuhaler in young children suspected of asthma. Eur Respir J 7: 740–742. doi: 10.1183/09031936.94.07040740
[9]
Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, et al. (1997) Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 10: 2023–2028. doi: 10.1183/09031936.97.10092023
[10]
Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, et al. (1998) Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J 11: 350–354. doi: 10.1183/09031936.98.11020350
[11]
De Boeck K, Alifier M, Warnier G (1999) Is the correct use of a dry powder inhaler (Turbohaler) age dependent? J Allergy Clin Immunol 103: 763–767. doi: 10.1016/s0091-6749(99)70417-3
[12]
Kamps AWA, Van Ewijk B, Roorda RJ, Brand PLP (2000) Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 29: 39–42. doi: 10.1002/(sici)1099-0496(200001)29:1<39::aid-ppul7>3.3.co;2-7
[13]
Kamps AWA, Brand PLP, Roorda RJ (2002) Determinants of correct inhalation technique in children attending a hospital-based asthma clinic. Acta Paediatr 91: 159–163. doi: 10.1111/j.1651-2227.2002.tb01688.x
[14]
Pedersen S, Steffensen G (1986) Fenoterol powder inhaler technique in children: influence of inspiratory flow rate and breath-holding. Eur J Respir Dis 68: 207–214.
[15]
Pedersen S (1986) How to use a rotahaler. Arch Dis Child 61: 11–14. doi: 10.1136/adc.61.1.11
[16]
Kamps AWA, Brand PLP, Roorda RJ (2004) Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 37: 65–70. doi: 10.1002/ppul.10410
[17]
Bisgaard H, Klug B, Sumby BS, Burnell PKP (1998) Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 11: 1111–1115. doi: 10.1183/09031936.98.11051111
[18]
Amirav I, Newhouse MT, Mansour Y (2005) Measurement of peak inspiratory flow with In-Check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 39: 447–451. doi: 10.1002/ppul.20180
[19]
Desager KN, Geldhof J, Claes R, De Backer W (2006) Measurement of inspiratory flow through three different dry powder inhalation devices using In-Check in children with asthma. Pediatr Asthma Allergy Immunol 19: 6–13. doi: 10.1089/pai.2006.19.6
[20]
Adachi YS, Adachi Y, Itazawa T, Yamamoto J, Murakami G, et al. (2006) Ability of preschool children to use dry powder inhalers as evaluated by In-Check Meter. Pediatr Int 48: 62–65. doi: 10.1111/j.1442-200x.2006.02173.x
[21]
Tiddens HA, Geller DE, Challoner P, Speirs RJ, Kesser KC, et al. (2006) Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med 19: 456–465. doi: 10.1089/jam.2006.19.456
[22]
Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, et al. (2011) What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 37: 1308–1331. doi: 10.1183/09031936.00166410
[23]
De Koning JP, Van der Mark TW, Coenegracht PMJ, Tromp TFJ, Frijlink HW (2002) Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm 234: 257–266. doi: 10.1016/s0378-5173(01)00969-3
[24]
Koopman M, Zanen P, Kruitwagen CLJJ, van der Ent CK, Arets HGM (2011) Reference values for paediatric pulmonary function testing: The Utrecht dataset. Respir Med 105: 15–23. doi: 10.1016/j.rmed.2010.07.020
